Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report

<p>Abstract</p> <p>Introduction</p> <p>Pure red cell aplasia due to anti-epoetin antibodies is a known complication of epoetin therapy for anemia due to chronic kidney disease. This disease has not previously been well described in the setting of therapy for chronic hep...

Full description

Bibliographic Details
Main Authors:	Behler Caroline M, Terrault Norah A, Etzell Joan E, Damon Lloyd E
Format:	Article
Language:	English
Published:	BMC 2009-07-01
Series:	Journal of Medical Case Reports
Online Access:	http://www.jmedicalcasereports.com/content/3/1/7335

Similar Items

Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia
by: S A Mahajan, et al.
Published: (2015-01-01)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
by: Steven Fishbane, et al.
Published: (2019-09-01)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
by: Muhammad Umer Siddiqui, et al.
Published: (2017-01-01)

A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
by: J Wilson, et al.
Published: (2007-04-01)

Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
by: Seyed Ashkan Hosseini, et al.
Published: (2020-06-01)

Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients
by: Amel Harzallah, et al.
Published: (2015-01-01)

Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient
by: Yasuki Shingu, et al.
Published: (2020-07-01)

INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
by: I. Dudar, et al.
Published: (2014-03-01)

Epoetin alfa ja namaluva nefrotoksicnosta inducirana so cisplatin kaj staorci
by: Dimce Zafirov, et al.
Published: (2006-06-01)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
by: Arrieta J, et al.
Published: (2014-10-01)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
by: E.J.F. Santos, et al.
Published: (2018-05-01)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
by: Natasha Irrera, et al.
Published: (2015-01-01)

The Use of Epoetin-α in Revision Knee Arthroplasty
by: Lawrence A. Delasotta, et al.
Published: (2012-01-01)

Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
by: Pilar M Samper Ots, et al.
Published: (2008-01-01)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
by: Bhanu Prasad, et al.
Published: (2020-06-01)

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
by: Giovanni Rosti, et al.
Published: (2017-01-01)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
by: Galli L, et al.
Published: (2015-03-01)

Effects of Hemoglobin Normalization with Epoetin in Chronic Kidney Disease
by: Furuland, Hans
Published: (2005)

Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
by: Kurtz JE, et al.
Published: (2016-10-01)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
by: Jay B. Wish, et al.
Published: (2019-09-01)

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
by: Iain RJ Macpherson, et al.
Published: (2009-03-01)

Shift in Balance of IV Iron-to-Epoetin USE: 2008-2011
by: Alex Yang, et al.
Published: (2012-06-01)

CIRCULATING ANTIBODIES TO ERYTHROPOIETIN ARE ASSOCIATED WITH LOWER EFFICACY OF RECOMBINANT EPOETIN TREATMENT IN PATIENTS UNDERGOING HAEMODIALYSIS
by: V. D. Nazarov, et al.
Published: (2018-01-01)

Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation
by: Annie K. Hung, et al.
Published: (2015-01-01)

Own experience of treatment by epoetin-α (Eralfon®) of chemotherapy induced anemia
by: S A Bolshakova, et al.
Published: (2017-01-01)

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
by: Ohashi N, et al.
Published: (2012-03-01)

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach
by: Ly Minh Nguyen, et al.
Published: (2020-10-01)

Évaluation pharmacodynamique et sécurité d'emploi de l'Époétine alfa chez les patients aux soins intensifs
by: Darveau, Martin
Published: (2016)

A Multicenter assessment of the on-label and off-label usage of erythropoietic agents( epoetin alfa and darbepoetin alfa) in critically ill ICU patients : A retrospective study
by: Lee, Seina Park
Published: (2006)

Higher‐risk myelodysplastic syndrome in an elderly patient: Long‐term partial remission with low‐dose prednisone, G‐CSF, and epoetin alfa
by: Anwarul Islam
Published: (2021-09-01)

Epoetin Delta Reduces Oxidative Stress in Primary Human Renal Tubular Cells
by: Annelies De Beuf, et al.
Published: (2010-01-01)

Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
by: Gilbertson David T, et al.
Published: (2013-02-01)

Methoxy polyethylene glycol epoetin beta and the treatment of anaemia in chronic heart failure
by: K. Kh. Zakhidova, et al.
Published: (2013-06-01)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
by: November McGarvey, et al.

Acquired pure red cell aplasia following recombinant erythropoietin (darbepoetin-alfa) therapy
by: Somanath Padhi, et al.
Published: (2020-01-01)

DOSE ADJUSTMENT PRACTICES OF PEGINESATIDE VS. EPOETIN IN EMERALD 1 AND 2 PIVOTAL TRIALS
by: Amit Sharma, et al.
Published: (2012-06-01)

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
by: Davis-Ajami ML, et al.
Published: (2014-04-01)

The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data
by: Shukla Rakesh, et al.
Published: (2009-02-01)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017-10-01)

Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?
by: Marone Claudio, et al.
Published: (2006-09-01)